Log in
TSE:COM

138267 (COM.TO) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume9,197 shs
Average Volume19,585 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-6776905
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive COM News and Ratings via Email

Sign-up to receive the latest news and ratings for COM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











138267 (COM.TO) (TSE:COM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of 138267 (COM.TO)?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 138267 (COM.TO) in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for 138267 (COM.TO)
.

Who are some of 138267 (COM.TO)'s key competitors?

What other stocks do shareholders of 138267 (COM.TO) own?

Who are 138267 (COM.TO)'s key executives?

138267 (COM.TO)'s management team includes the following people:
  • Dr. William L. Hunter, Pres, CEO & Director (Age 55)
  • Ms. Sheila M. Grant MBA, Chief Operating Officer
  • Mr. David D. McMasters, Gen. Counsel (Age 59)
  • Mr. Hugues Sachot, Chief Commercial Officer
  • Mr. Justin A. Renz, Chief Financial Officer (Age 46)

What is 138267 (COM.TO)'s stock symbol?

138267 (COM.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "COM."

How do I buy shares of 138267 (COM.TO)?

Shares of COM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is 138267 (COM.TO)?

138267 (COM.TO) has a market capitalization of C$0.00.

What is 138267 (COM.TO)'s official website?

The official website for 138267 (COM.TO) is www.cardiome.com.

How can I contact 138267 (COM.TO)?

138267 (COM.TO)'s mailing address is 1441 Creekside Dr 6th Floor, VANCOUVER, BC V6J 4S7, Canada. The biopharmaceutical company can be reached via phone at +1-604-6776905.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.